Hormone and Information Processing Study (HIP)
Testosterone Supplementation in Men With MCI
研究概览
详细说明
Natural age related declines in testosterone (T) are associated with decreases in cognitive abilities independent of health status. Low T levels over time are associated with increased risk for developing Alzheimer's disease (AD). These findings suggest that men with low T levels are most at risk for age-related cognitive decline and AD and therefore most likely to benefit from T supplementation to prevent the development of AD or age-associated cognitive decline. The current study will assess cognition, mood, and cerebral spinal fluid (CSF) biomarker response to T supplementation in older men with mild cognitive impairment (MCI) and low T levels.
Participants will be randomized to either receive T treatment or a placebo for six months. Participants will come in for about five visits within the span of six months where they will complete cognitive & memory tests, fill out mood questionnaires, and have their blood drawn to monitor the medication level. A sample of blood will also be taken at one visit to test for apolipoprotein E (APOE), which is a genetic risk factor associated with AD. Participants will have the option to get a spinal tap in order to measure biological markers associated with Alzheimer's disease including beta-amyloid 1-40, 42, total-tau, and phosphorylated-tau-181-231. This will require an additional two visits.
研究类型
注册 (实际的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
Washington
-
Seattle、Washington、美国、98108
- VA Puget Sound Health Care Systems
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Male 60-90 years of age
- Diagnosis of mild cognitive impairment (MCI)
- Low testosterone level
- Primary language is English
- Availability of an informant who knows the participant well enough to answer questions
- Stable medications for the previous 3 months
- Normal complete blood count (CBC), and no clinically significant blood chemistry
- American Urological Association (AUA) symptom score less than or equal to 19
- Body Mass Index (BMI) less than 33 and stable weight in the previous year
Exclusion Criteria:
- Prior history of prostate cancer or prostate specific antigen level greater than 4.0ng/ml
- Peripheral or vascular disease
- Significant history of alcohol abuse, current alcohol abuse (more than 2 drinks per day), or other substance abuse
- History of severe head injury (with loss of consciousness greater than 30 minutes)
- Significant neurological illness, such as Parkinson's disease, seizure disorder, multiple sclerosis, major stoke
- Smokes cigarettes
- Major psychiatric illness, such as schizophrenia or bipolar disorder
Prohibited Medications:
- Anti-convulsants
- Anti-psychotics
- Sedating antihistamines
- Sedative/hypnotics
- Benzodiazepines
- Hormone or testosterone regimens
- Gonadotropin-releasing hormone (GNRH) antagonists
- Flutamide
- Anti-depressants and/or anti-cholinesterase inhibitors, but acceptable if on stable dose for 3 months or more
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
安慰剂比较:2个
|
applied topically daily for six months
|
实验性的:Study drug; testosterone transdermal gel
Dose will be adjusted as needed to maintain a target total T level of 500-900 ng/dl
|
50-100mg applied topically daily for six months
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Behavioral & Mood Measure: Profile of Mood States (POMS)
大体时间:Baseline, 3 and 6 months
|
Values represent self evaluation of vigor-activity.
The scale compares t-scores of participants to published norms (range 0-100), and higher scores indicate elevated emotion in subscale.
Higher t-scores in vigor-activity subscale are considered favorable.
Month 3 and Month 6 values display change from baseline.
|
Baseline, 3 and 6 months
|
Cognitive Changes Measured by Neuropsychological Tests: Rey Auditory Verbal Learning Test
大体时间:Baseline, 3 and 6 months
|
Values represent total score in Long Delay Word List Recall.
Higher score indicates higher level of functioning (range 0-15).
Month 3 and Month 6 indicate change from baseline.
|
Baseline, 3 and 6 months
|
Geriatric Depression Scale (GDS)
大体时间:Baseline, Month 3, Month 6
|
Values represent self evaluation of depression (range 0-30).
Higher scores indicate a more depressed mood.
Month 3 and Month 6 indicate change from baseline.
|
Baseline, Month 3, Month 6
|
Short-Form Health Survey (SF-36)
大体时间:Baseline, Month 3, Month 6
|
Self assessment of Physical Functioning in Health Survey.
Higher scores indicate a higher level of functioning (range 0-100).
Month 3 and 6 values represent change from baseline in subscale.
|
Baseline, Month 3, Month 6
|
合作者和调查者
调查人员
- 首席研究员:Monique Cherrier, PhD、University of Washington
出版物和有用的链接
一般刊物
- Cherrier MM, Asthana S, Plymate S, Baker L, Matsumoto AM, Peskind E, Raskind MA, Brodkin K, Bremner W, Petrova A, LaTendresse S, Craft S. Testosterone supplementation improves spatial and verbal memory in healthy older men. Neurology. 2001 Jul 10;57(1):80-8. doi: 10.1212/wnl.57.1.80.
- Cherrier MM, Matsumoto AM, Amory JK, Ahmed S, Bremner W, Peskind ER, Raskind MA, Johnson M, Craft S. The role of aromatization in testosterone supplementation: effects on cognition in older men. Neurology. 2005 Jan 25;64(2):290-6. doi: 10.1212/01.WNL.0000149639.25136.CA.
- Cherrier MM, Matsumoto AM, Amory JK, Asthana S, Bremner W, Peskind ER, Raskind MA, Craft S. Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment. Neurology. 2005 Jun 28;64(12):2063-8. doi: 10.1212/01.WNL.0000165995.98986.F1.
- Cherrier MM, Matsumoto AM, Amory JK, Johnson M, Craft S, Peskind ER, Raskind MA. Characterization of verbal and spatial memory changes from moderate to supraphysiological increases in serum testosterone in healthy older men. Psychoneuroendocrinology. 2007 Jan;32(1):72-9. doi: 10.1016/j.psyneuen.2006.10.008. Epub 2006 Dec 4.
- Lu PH, Masterman DA, Mulnard R, Cotman C, Miller B, Yaffe K, Reback E, Porter V, Swerdloff R, Cummings JL. Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men. Arch Neurol. 2006 Feb;63(2):177-85. doi: 10.1001/archneur.63.2.nct50002. Epub 2005 Dec 12.
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- 29975-A
- R01AG027156 (美国 NIH 拨款/合同)
- 1R01AG027156-01A2 (美国 NIH 拨款/合同)
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
testosterone gel的临床试验
-
Geneve TEAM AmbulancesUniversity Hospital, Geneva; ESAMB - College of Higher Education in Ambulance Care; Ambulances...完全的
-
Seoul National University Hospital完全的